Recently, the approval was extended to patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who had received endocrine-based therapy and at least two additional systemic therapies for advanced disease. The gene discussed is ERBB2; the disease is breast carcinoma.